EFFECT OF PIPER NIGRUM ON IN-VITRO RELEASE OF RIFAMPICIN MICROSPHERES
Tuberculosis therapy remains a challenge even today, mainly due to the problems of bacterial resistance, side effects and low patient compliance, associated with anti-tubercular drugs. A bioenhancer is an agent capable of enhancing bioavailability and bioefficacy of a particular drug with which it is combined, without any typical pharmacological activity of its own at the dose used. Microspheres are one of the multiparticulate drug delivery systems prepared to obtain prolonged drug delivery, to improve its bioavailability or stability and to target drug to specific sites. Rifampicin is an important component of fixed dose combination used in first line therapy of tuberculosis. In the present study, we attempted an innovative approach to overcome the above-mentioned problems of tuberculosis therapy by combining both these approaches of microspheres and bioenhancers. Small amount of herbal extract of Piper nigrum were incorporated as a bioenhancer in variable amount for each dose of rifampicin.
The drug loading efficiency and in-vitro release behavior of loaded microspheres were found to be satisfactory. Prolonged release of the drug from the microspheres was demonstrated in a simulated intestinal fluid. In-vitro release of rifampicin from the microspheres containing variable fractions of bioenhancer showed significant increase in release profile i.e. 80.24 and 86.16percent in formulation containing bioenhancer against 44.54percent for the formulation without bioenhancer prepared by complex coacervation method.Â
Keywords: Tuberculosis, Microspheres, Drug release, Bioenhancer, Rifampicin, Piper nigrum
2. Zumla A., Raviglione M., Hafner R., Reyn C.F. Tuberculosis. The New England Journal of Medicine. 2013;368(8): 745-755.
3. Rang H.P., Dale M.M., Ritter J.M., Flower R.J. Antibacterial drugs. In: Rang and Daleâ€™s Pharmacology. 6th ed., Churchill Livingstone. Elsevier Health Science Rights Department, Philadelphia, USA. 2007
4. Chakraborty A.K. Epidemiology of tuberculosis: current status in India. Indian Journal of Medical Research. 2004; 120: 248-276.
5. Toit L.C., Pillay V., Danckwerts M.P. Tuberculosis chemotherapy: current drug delivery approaches. Respiratory Research. 2006; 7(118): 1-18.
6. Johri R.K., Zutshi U. An Ayurvedic formulation â€˜Trikatuâ€™ and its constituents. Journal of Ethnopharmacology. 1992; 37:85-91.
7. Ankola D.D., Beniwal V., Singh D., Kumar M.N. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. European Journal of Pharmaceutical Science. 2009; 37:223-230.
8. Qazi G.N., Bedi K.L., Johri R.K. et al., Bioavailability enhancing activity of Carum carvi extracts and fractions thereof. United States Patent Number, US20030228381A1. 2003.
9. Pingale P.L., Ravindra R.P. Effect of Piper nigrum on in-vitro release of Isoniazid from oral microspheres. International Journal of Pharm and Bio Sciences. 2013; 4(1):1027- 1036.
10. Kokate C.K., Purohit A.P., Gokhale S.B., Pharmacognosy. 46th ed. Nirali Prakashan, Pune. 2010.
11. Kolhe S.R., Borole P., Patel U. Extraction and Evaluation of Piperine from Piper nigrum Linn. International Journal of Applied Biology and Pharmaceutical Technology. 2011; 2(2):144-149.
12. Indian Pharmacopoeia-2010. Indian Pharmacopoeia Commission, Ministry of Health and Family Welfare, New Delhi, India 6th edition. Volume III. p. 2522.
13. The Ayurvedic Pharmacopoeia of India-2007. Department of Ayush, Ministry of Health and Family Welfare, Government of India. Part I Volume II. 141.
14. Barrow E. L. W., Winchester G. A., Staas J. K., Quenelle D. C., Barrow W. W. Use of Microsphere Technology for Targeted Delivery of Rifampin to Mycobacterium tuberculosis-Infected Macrophages. Antimicrobial Agents and Chemotherapy. 1998; 42(10), 2682-2689.
15. Sarfaraz, M.D., Hiremath, D., Chowdary, K. P. R. Formulation and characterization of rifampicin microcapsules. Indian Journal of Pharmaceutical Sciences. 2010; 72(1): 101-105.
16. Brennan P.J., Young D.B. Handbook of Anti-Tuberculosis Agents. Tuberculosis. 2008; 88(2): 85-170.
17. Dutt M., Khuller G.K. Liposomes and PLG microparticles as sustained release antitubercular drug carriersâ€”an in vitroâ€“in vivo study. International Journal of Antimicrobial Agents. 2001; 18:245-252.
18. Pandey P., Khuller G.K. Chemotherapeutic potential of alginateâ€“chitosan microspheres as anti-tubercular drug carriers. Journal of Antimicrobial Chemotherapy. 2004; 53, 635-640.
19. Rungseevijitprapa W. Development of oral isoniazid and rifampicin microspheres. Isan Journal of Pharmaceutical Sciences. 2009; 5(1), 63-73.
20. Pingale P.L., Ravindra R.P. Effect of process variables and co-administration of bioenhancer on in-vitro release of rifampicin from oral microspheres. American Journal of PharmTech Research. 2013; 3(1):945-956.
21. Ranga Rao KV, Buri P. A novel in situ method to test polymers and coated microparticles for bioadhesion. International Journal of Pharmaceutics. 1989; 52, 265-270.
22. Sarfaraz MD, Hiremath D, Chowdary KPR. Formulation and characterization of rifampicin microcapsules. Indian Journal of Pharmaceutical Sciences. 2010; 72(1): 101-105.
23. Desai J.V., Patil J.S., Kulkarni R.V., Marapur S.C., Dalavi V.V. Alginate based microparticulate oral drug delivery system for rifampicin. Research Journal of Pharmacy and Technology. 2009; 2(2): 301-303.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.